By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. Mizuho's price target would suggest a potential downside of 40.61% from the company's current price.
A number of other research firms have also recently issued reports on VRX. Wells Fargo & Company reiterated an "underperform" rating on shares of Valeant Pharmaceuticals International in a report on Monday, June 12th. BMO Capital Markets lifted their price target on Valeant Pharmaceuticals International to $21.00 in a report on Wednesday, March 1st. Vetr cut shares of Valeant Pharmaceuticals International from a "strong-buy" rating to a "buy" rating and set a $14.82 price target for the company.in a research report on Monday, May 22nd. J P Morgan Chase & Co reaffirmed a "hold" rating on shares of Valeant Pharmaceuticals International in a research report on Tuesday, May 9th. Scotiabank lowered their price target on shares of Valeant Pharmaceuticals International from $15.00 to $12.00 and set a "sector perform" rating for the company in a research report on Wednesday, April 26th.
Stock Volume Ramping Up Mid-Session: Alibaba Group Holding Limited (NYSE:BABA)
Finally, Raymond James Trust N.A. raised its position in shares of Alibaba Group Holding Limited by 0.9% in the first quarter. Alibaba Group Holding Limited's P/E stands at 54.06, while the P/S is at 14.37 and earnings per share this year of -39.10%.
Among 25 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 6 have Buy rating, 3 Sell and 16 Hold. Ftb Advsrs reported 0.01% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). The stock declined 0.22% or $0.03 reaching $13.44 per share. Armstrong Henry H Associates Inc who had been investing in Valeant Pharmaceuticals for a number of months, seems to be less bullish one the $4.82 billion market cap company. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $32.74. The company's 50-day moving average price is $16.72 and its 200 day moving average price is $17.24. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 48.51% since June 20, 2016 and is downtrending. The specialty pharmaceutical company reported $2.80 EPS for the quarter, beating the consensus estimate of $0.87 by $1.93. For our stock under consideration here, Valeant Pharmaceuticals International, Inc. The company had revenue of $2.11 billion during the quarter, compared to analysts' expectations of $2.17 billion. During the same period in the previous year, the firm earned ($1.08) EPS.
ILLEGAL ACTIVITY NOTICE: This article was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and global copyright & trademark law. Pinebridge Invs Limited Partnership reported 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX).
PGA Tour to start blood testing next season
Tuesday morning, the PGA Tour announced multiple changes to its drug testing program , with one being of major significance. The PGA Tour will begin blood testing players next season as it toughens its stance on doping.
In related news, Director Schutter Richard U. De purchased 20,000 shares of the stock in a transaction on Thursday, May 11th. The shares were acquired at an average price of $13.90 per share, with a total value of $278,000.00. Following the completion of the acquisition, the director now directly owns 70,572 shares in the company, valued at approximately $980,950.80. Institutional investors own 50.45% of the company's stock. It dropped, as 82 investors sold VRX shares while 87 reduced holdings. Equities analysts expect that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current fiscal year. Prudential Public Ltd Company accumulated 75,000 shares or 0% of the stock. OLD Mutual Customised Solutions Proprietary Ltd. now owns 11,900 shares of the specialty pharmaceutical company's stock worth $131,000 after buying an additional 9,300 shares in the last quarter. Financial Architects Inc increased its stake in Valeant Pharmaceuticals International by 18.6% in the first quarter. Finally, Stonehill Capital Management LLC purchased a new stake in Valeant Pharmaceuticals International during the fourth quarter worth approximately $11,151,000. The Cypress Funds Llc holds 260,000 shares with $3.78 million value, down from 440,000 last quarter.
Paulson supported Valeant in 2014 during its unsuccessful attempt to buy Botox maker Allergan Inc., which eventually went to a rival bidder.
Monday morning rain, with afternoon sun
Notably cooler conditions are expected for the latter half of the work week and through the weekend. Today's forecast calls for scattered showers, with thunderstorms also possible after 11 a.m.
- Turkey's Erdogan condemns Qatar blockade 'death sentence'
- Infantino Defends VAR At Confederations Cup
- Carla Fendi, philanthropist and fashion force, dies at 79
- Cosby faces 2nd sex assault trial after jury deadlocks
- Revenue Estimates Analysis The Procter & Gamble Company (PG)
- United States says it shot down Iranian-made drone in Syria
- Seattle officer in fatal shooting: 'I don't have a taser'
- Trump meets Poroshenko for brief 'drop-in' visit
- Brutal slaying near mosque stemmed from road rage
- New al-Qaeda linked group claims responsibility for Mali resort attack